Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Bumetanide
C P Pharmaceuticals Ltd
C03CA02
Bumetanide
1mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02020200
Top of page cut-off to middle of registration mark: 23mm. Registration Pitch: 210mm -0.45mm (Sheet depth / cut-off length: 210mm) Pharma code 771 BUMETANIDE 1 MG AND 5 MG TABLETS READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. 1. WHAT BUMETANIDE IS AND WHAT IT IS USED FOR 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE BUMETANIDE 3. HOW TO TAKE BUMETANIDE 4. POSSIBLE SIDE EFFECTS 5. HOW TO STORE BUMETANIDE 6. CONTENTS OF THE PACK AND OTHER INFORMATION WHAT BUMETANIDE IS AND WHAT IT IS USED FOR • Bumetanide is a type of medicine called a diuretic which increases the amount of water (urine) passed • Bumetanide is used to treat excess fluid accumulation in the body (oedema) which can be caused by heart, liver, or kidney disease. WHAT YOU NEED TO KNOW BEFORE YOU TAKE BUMETANIDE DO NOT TAKE BUMETANIDE IF YOU: • are allergic (hypersensitive) to bumetanide or any of the other ingredients of this medicine • are in the first 3 months of pregnancy or breast-feeding • suffer from severe liver disease, or are in a coma due to severe liver problems • suffer from a severe imbalance of water and salts in the body • are producing less urine than usual, or no urine at all. WARNINGS AND PRECAUTIONS Tell your doctor before you start to take this medicine if you: • are on a low salt diet • have kidney problems. Your doctor may give you regular blood and urine tests whilst you are taking this medicine. If you see another doctor or go into hospital, let him or the staff know what medicines you are taking. OTHER MEDICINES AND BUMETANIDE Tell y Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Bumetanide Tablets 1mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 1mg of bumetanide. Excipient with known effect: Contains 50.6 mg of lactose monohydrate For the full list of excipients,see section6.1. 3 PHARMACEUTICAL FORM Tablet White to off-white, round, normal convex, uncoated tablet of approximately 6 mm, plain on one side with a breakline and ‘1’ centrally above ‘BMT’ on the other side. The tablet can be divided into equal doses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Bumetanide Tablets 1mg are indicated in adults whenever diuretic therapy is required in the treatment of oedema, for example that associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. In oedema of cardiac or renal origin where high doses of a potent short acting diuretic are required, Bumetanide Tablets 5mg may be used in adults. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The dose should be carefully titrated in each patient according to the patient’s response and the required therapeutic activity. _Adults: _ Most patients require a daily dose of 1mg which can be given as a single morning or early evening dose. Depending on the patient’s response, a second dose can be given six to eight hours later. In refractory cases, the dose can be increased until a satisfactory diuretic response is obtained, or infusions of Bumetanide can be given. The maximum daily dosage is 10mg. _Paediatric population: _ The medicinal product is not recommended for children under 12 years of age as there is limited information on safety, efficacy and dosage in children. _ _ _Elderly: _ Adjust dosage according to response; a dose of 0.5mg of bumetanide per day may be sufficient in some elderly patients. Method of administration For oral administration. 4.3 CONTRAINDICATIONS • Hypersensitivity to the active substance, sulfonylureas or any of the excipients listed in section 6.1. • Oligur Read the complete document